Remarkably, our results indicate that SART3 exhibits excellent diagnostic performance in the Guangxi cohort (AUC = 0.931) (Figure 4C), and that its overexpression is associated with a poorer prognosis for HCC patients (p = 0.018) (Figure 4D). Here, SART3 is linked to hepatocellular carcinoma.